{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "NMN raises blood NAD; older-adult gait signals are tentative and inconsistent, with no established broader physical or longevity benefit.",
  "implications": "Primary SC2 tentatively crosses Δ, with Low confidence, because the registered physical-function gate includes a genuine assigned secondary gait contrast. The quality concerns—multiple endpoints, incomplete twelve-week observations, an older trial allocation error and exploratory testing—are not hidden or converted into an unstated primary-endpoint requirement. Functional benefit is inconsistent across measures and contexts, and a separate emerging longer-dose trial adds a null boundary. Evidence does not establish broad strength/exercise efficacy, isolated NAD necessity or human longevity. SC1/SC3 marker-to-clinical inference and SC4 molecule equivalence remain separately bounded.",
  "limitations": "70 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}